New Drug Development in Hematology

The development of antibiotic resistance in particular stems from the drugs targeting only specific bacterial molecules. Because the drug is so specific, any mutation in these molecules will interfere with or negate its destructive effect, resulting in antibiotic resistance. Known as Drug delivery Conditions treated with combination therapy include tuberculosis, leprosy, cancer, malaria, and HIV/AIDS. One major benefit of combination therapies is that they reduce development of drug resistance, since a pathogen or tumor is less likely to have resistance to multiple drugs simultaneously. Artemisinin-based monotherapies for malaria are explicitly discouraged to avoid the problem of developing resistance to the newer treatment. Drug Induced Blood Disorders causes of sickle cell anemia,pale skin non steroids anti inflammatory drugs which causes ulcers Using drug repositioning, pharmaceutical companies have achieved a number successes, for example Pfizer's Viagra in erectile dysfunction and Celgene's thalidomide in severe erythema nodosum leprosum. Smaller companies, including Ore Pharmaceuticals, Biovista, Numedicus, Melior Discovery and SOM Biotech are also performing drug repositioning on a systematic basis. These companies use a combination of approaches including in silico biology and in vivo/in vitro experimentation to assess a compound and develop and confirm hypotheses concerning its usage for new indications.

  • Drug Resistance Control
  • Multiple Simultaneous Diseases
  • Approval Probabilities
  • Drug Induced Blood Disorders
  • Non-Steroidal Anti-Inflammatory Drugs
  • Drug Repurposing

Related Conference of New Drug Development in Hematology

March 18-19, 2019

16th World Hematology Congress

Rome, Italy
June 17-18, 2019

2nd Hematologists Global Summit 2019

Osaka, Japan
October 23-24, 2019

13th World Congress on Haematology and Oncology

| Radisson Narita | Tokyo, Japan

New Drug Development in Hematology Conference Speakers